NASDAQ:APLT

Applied Therapeutics Stock Forecast, Price & News

$17.52

-0.68 (-3.74 %)

(As of 07/27/2021 04:45 PM ET)

Add

Compare

Today's Range

$16.26

▼

$18.18

50-Day Range

$14.96

▼

$25.04

52-Week Range

$13.58

▼

$33.34

Volume85,296 shs

Average Volume108,384 shs

Market Capitalization$456.94 million

P/E RatioN/A

Dividend YieldN/A

Beta1.16

30 days | 90 days | 365 days | Advanced Chart

Receive APLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Applied Therapeutics

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Contrasting Applied Therapeutics (NASDAQ:APLT) and Assertio (NASDAQ:ASRT)
July 23, 2021 | americanbankingnews.com

Applied Therapeutics (NASDAQ:APLT) Stock Price Down 5.3%
July 22, 2021 | americanbankingnews.com

Applied Therapeutics (NASDAQ:APLT) Shares Gap Down to $19.97
July 21, 2021 | americanbankingnews.com

Applied Therapeutics (NASDAQ:APLT) Trading 7.7% Higher
July 20, 2021 | americanbankingnews.com

Applied Therapeutics, Inc. (NASDAQ:APLT) Insider Riccardo Perfetti Sells 4,467 Shares
July 15, 2021 | americanbankingnews.com

Applied Therapeutics Added to Russell Microcap® Index
June 28, 2021 | finance.yahoo.com

Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
June 21, 2021 | finance.yahoo.com

Applied Therapeutics Gets Fast Track Designation from FDA
June 17, 2021 | finance.yahoo.com

Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder
June 17, 2021 | markets.businessinsider.com

Applied Therapeutics Gets FDA Fast-Track Designation for AT-007 in Galactosemia >APLT
June 17, 2021 | marketwatch.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APLT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.appliedtherapeutics.com
Phone212-220-9226
Employees24
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.64 per share
Price / Book4.81

Profitability

EPS (Most Recent Fiscal Year)($4.28)
Net Income$-93,960,000.00
Net MarginsN/A
Return on Equity-99.13%
Return on Assets-82.30%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares26,081,000
Market Cap$456.94 million
Next Earnings Date8/10/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.91 out of 5 stars

Medical Sector

762nd out of 2,218 stocks

Pharmaceutical Preparations Industry

367th out of 869 stocks

3.3 Analyst's Opinion

Consensus Rating
Applied Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $45.50, Applied Therapeutics has a forecasted upside of 160.3% from its current price of $17.48.
Amount of Analyst Coverage
Applied Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.1 Community Rank

Outperform Votes
Applied Therapeutics has received 54 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Applied Therapeutics has received 34 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Applied Therapeutics has received 61.36% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Applied Therapeutics and other stocks. Vote “Outperform” if you believe APLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Applied Therapeutics does not currently pay a dividend.
Dividend Growth
Applied Therapeutics does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $234,596.00 in company stock.
Percentage Held by Insiders
27.20% of the stock of Applied Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
56.83% of the stock of Applied Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Applied Therapeutics are expected to grow in the coming year, from ($4.49) to ($4.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Applied Therapeutics is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied Therapeutics is -3.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Applied Therapeutics has a P/B Ratio of 4.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Applied Therapeutics (NASDAQ:APLT) Frequently Asked Questions

Is Applied Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Applied Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Applied Therapeutics stock.
View analyst ratings for Applied Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Applied Therapeutics?

Wall Street analysts have given Applied Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Applied Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Applied Therapeutics' next earnings date?

Applied Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Applied Therapeutics.

How were Applied Therapeutics' earnings last quarter?

Applied Therapeutics, Inc. (NASDAQ:APLT) issued its quarterly earnings data on Monday, May, 10th. The company reported ($1.00) EPS for the quarter, topping the Zacks' consensus estimate of ($1.01) by $0.01.
View Applied Therapeutics' earnings history.

How has Applied Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Applied Therapeutics' stock was trading at $29.59 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, APLT stock has decreased by 40.8% and is now trading at $17.52.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for APLT?

3 brokerages have issued 1 year price objectives for Applied Therapeutics' stock. Their forecasts range from $18.00 to $85.00. On average, they anticipate Applied Therapeutics' stock price to reach $45.50 in the next twelve months. This suggests a possible upside of 159.7% from the stock's current price.
View analysts' price targets for Applied Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Applied Therapeutics' key executives?

Applied Therapeutics' management team includes the following people:

Dr. Shoshana Shendelman Ph.D., Chair of the Board of Directors, Founder, Pres, CEO & Sec. (Age 42, Pay $895.12k)
Dr. Charles Silberstein M.D., CFA, CFO & Head of Bus. Devel. (Age 50, Pay $378.2k) (LinkedIn Profile)
Dr. Riccardo Perfetti, Chief Medical Officer (Age 62, Pay $672.14k) (LinkedIn Profile)
Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 52)
Mr. Adam Hansard, Chief Commercial Officer (Age 45)

Who are some of Applied Therapeutics' key competitors?

Some companies that are related to Applied Therapeutics include Xencor (XNCR), MorphoSys (MOR), Global Blood Therapeutics (GBT), Constellation Pharmaceuticals (CNST), Prelude Therapeutics (PRLD), NGM Biopharmaceuticals (NGM), Amarin (AMRN), Zymeworks (ZYME), PMV Pharmaceuticals (PMVP), Avid Bioservices (CDMO), Indivior (INVVY), MacroGenics (MGNX), COMPASS Pathways (CMPS), Aurinia Pharmaceuticals (AUPH) and Amneal Pharmaceuticals (AMRX).
View all of APLT's competitors.

What other stocks do shareholders of Applied Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Therapeutics investors own include Enterprise Products Partners (EPD), Pfizer (PFE), Advanced Micro Devices (AMD), Energy Transfer (ET), Micron Technology (MU), NVIDIA (NVDA), Verizon Communications (VZ), AbbVie (ABBV), The Walt Disney (DIS) and Raytheon Technologies (RTX).

When did Applied Therapeutics IPO?

(APLT) raised $60 million in an IPO on the week of May 13th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and UBS Investment Bank served as the underwriters for the IPO and Baird was co-manager.

What is Applied Therapeutics' stock symbol?

Applied Therapeutics trades on the NASDAQ under the ticker symbol "APLT."

How do I buy shares of Applied Therapeutics?

Shares of APLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Applied Therapeutics' stock price today?

One share of APLT stock can currently be purchased for approximately $17.52.

How much money does Applied Therapeutics make?

Applied Therapeutics has a market capitalization of $456.92 million. The company earns $-93,960,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

How many employees does Applied Therapeutics have?

Applied Therapeutics employs 24 workers across the globe.

What is Applied Therapeutics' official website?

The official website for Applied Therapeutics is www.appliedtherapeutics.com.

Where are Applied Therapeutics' headquarters?

Applied Therapeutics is headquartered at 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173.

How can I contact Applied Therapeutics?

Applied Therapeutics' mailing address is 340 MADISON AVENUE 19TH FLOOR, NEW YORK NY, 10173. The company can be reached via phone at 212-220-9226 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here